Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 11:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 333 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Recurrent Fallopian Tube Cancer Clear all
Recruiting Phase 1 Interventional

Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF

NCT03604315
View directory record Official record
Conditions
Breast Carcinoma, Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Solid Neoplasm
Interventions
Computed Tomography, Fludeoxyglucose F-18, Fluorine F 18 Fluorthanatrace, Positron Emission Tomography
Procedure · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 5, 2026, 11:26 AM EDT
Completed Phase 1 Interventional

Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum

NCT00005860
View directory record Official record
Conditions
Cancer
Interventions
floxuridine, leucovorin calcium, oxaliplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 25, 2011 · Synced Sep 5, 2026, 11:26 AM EDT
Terminated Not applicable Interventional

EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer

NCT00087191
View directory record Official record
Conditions
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor, Localized Extrahepatic Bile Duct Cancer, Localized Gallbladder Cancer, Localized Gastrointestinal Carcinoid Tumor, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Metastatic Gastrointestinal Carcinoid Tumor, Ovarian Sarcoma, Ovarian Stromal Cancer, Primary Peritoneal Cavity Cancer, Recurrent Adult Primary Liver Cancer, Recurrent Adult Soft Tissue Sarcoma, Recurrent Colon Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Recurrent Gastric Cancer, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Recurrent Small Intestine Cancer, Recurrent Uterine Sarcoma, Regional Gastrointestinal Carcinoid Tumor, Small Intestine Adenocarcinoma, Small Intestine Leiomyosarcoma, Small Intestine Lymphoma, Stage 0 Non-small Cell Lung Cancer, Stage I Adult Soft Tissue Sarcoma, Stage I Colon Cancer, Stage I Gastric Cancer, Stage I Non-small Cell Lung Cancer, Stage I Ovarian Epithelial Cancer, Stage I Ovarian Germ Cell Tumor, Stage I Pancreatic Cancer, Stage I Rectal Cancer, Stage I Uterine Sarcoma, Stage II Adult Soft Tissue Sarcoma, Stage II Colon Cancer, Stage II Gastric Cancer, Stage II Non-small Cell Lung Cancer, Stage II Ovarian Epithelial Cancer, Stage II Ovarian Germ Cell Tumor, Stage II Pancreatic Cancer, Stage II Rectal Cancer, Stage II Uterine Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage III Colon Cancer, Stage III Gastric Cancer, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage III Pancreatic Cancer, Stage III Rectal Cancer, Stage III Uterine Sarcoma, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Adult Soft Tissue Sarcoma, Stage IV Colon Cancer, Stage IV Gastric Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Stage IV Uterine Sarcoma, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
Interventions
EF5, motexafin lutetium, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Sep 5, 2026, 11:26 AM EDT
Terminated Phase 2 Interventional Results available

(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma

NCT01936974
View directory record Official record
Conditions
Ovarian Carcinoma, Fallopian Tube Carcinoma, Peritoneal Carcinoma
Interventions
Gemcitabine, Bevacizumab, Carboplatin, Cisplatin, Oxaliplatin
Drug
Lead sponsor
Western Regional Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Goodyear, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Sep 5, 2026, 11:26 AM EDT
Active, not recruiting Phase 1 Interventional Results available

TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors

NCT02142803
View directory record Official record
Conditions
Adult Glioblastoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Solid Neoplasm, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
Interventions
Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study, Sapanisertib
Biological · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts • Charlestown, Massachusetts • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 5, 2026, 11:26 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT01606241
View directory record Official record
Conditions
Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage IIA Breast Cancer, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Cancer, Stage IIB Breast Cancer, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Cancer, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Cancer, Stage IIIA Breast Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Breast Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Breast Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer
Interventions
Cyclophosphamide, Laboratory Biomarker Analysis, Multi-epitope Folate Receptor Alpha Peptide Vaccine
Drug · Other · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Sep 5, 2026, 11:26 AM EDT
Completed No phase listed Observational

Collecting Tumor Samples From Patients With Gynecological Tumors

NCT00897442
View directory record Official record
Conditions
Borderline Ovarian Clear Cell Tumor, Borderline Ovarian Serous Tumor, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Childhood Embryonal Rhabdomyosarcoma, Childhood Malignant Ovarian Germ Cell Tumor, Endometrioid Stromal Sarcoma, Gestational Trophoblastic Tumor, Malignant Mesothelioma, Malignant Ovarian Epithelial Tumor, Melanoma, Neoplasm of Uncertain Malignant Potential, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Paget Disease of the Vulva, Recurrent Cervical Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Germ Cell Tumor, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Recurrent Vaginal Carcinoma, Recurrent Vulvar Carcinoma, Stage I Ovarian Cancer, Stage I Uterine Corpus Cancer, Stage I Vaginal Cancer, Stage I Vulvar Cancer, Stage IA Cervical Cancer, Stage IA Fallopian Tube Cancer, Stage IA Ovarian Cancer, Stage IA Ovarian Germ Cell Tumor, Stage IB Cervical Cancer, Stage IB Fallopian Tube Cancer, Stage IB Ovarian Cancer, Stage IB Ovarian Germ Cell Tumor, Stage IC Fallopian Tube Cancer, Stage IC Ovarian Cancer, Stage IC Ovarian Germ Cell Tumor, Stage II Ovarian Cancer, Stage II Uterine Corpus Cancer, Stage II Vaginal Cancer, Stage II Vulvar Cancer, Stage IIA Cervical Cancer, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Cancer, Stage IIA Ovarian Germ Cell Tumor, Stage IIB Cervical Cancer, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Cancer, Stage IIB Ovarian Germ Cell Tumor, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Cancer, Stage IIC Ovarian Germ Cell Tumor, Stage III Borderline Ovarian Surface Epithelial-Stromal Tumor, Stage III Cervical Cancer, Stage III Uterine Corpus Cancer, Stage III Vaginal Cancer, Stage III Vulvar Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Ovarian Germ Cell Tumor, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Ovarian Germ Cell Tumor, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Ovarian Germ Cell Tumor, Stage IIIC Primary Peritoneal Cancer, Stage IV Borderline Ovarian Surface Epithelial-Stromal Tumor, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Stage IV Uterine Corpus Cancer, Stage IVA Cervical Cancer, Stage IVA Vaginal Cancer, Stage IVB Cervical Cancer, Stage IVB Vaginal Cancer, Stage IVB Vulvar Cancer, Uterine Corpus Cancer, Uterine Corpus Leiomyosarcoma, Vulvar Squamous Cell Carcinoma
Interventions
Laboratory Biomarker Analysis
Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1992
U.S. locations
187
States / cities
Fayetteville, Arkansas • Little Rock, Arkansas • Burbank, California + 128 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Sep 5, 2026, 11:26 AM EDT
Completed Phase 1Phase 2 Interventional Results available

VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

NCT00436501
View directory record Official record
Conditions
Fallopian Tube Cancer, Malignant Tumor of Peritoneum, Recurrent Ovarian Epithelial Cancer
Interventions
docetaxel, ziv-aflibercept, laboratory biomarker analysis, pharmacological study
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Houston, Texas • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Sep 5, 2026, 11:26 AM EDT
Completed Phase 2 Interventional Results available

Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma

NCT00768144
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
Sunitinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 23, 2018 · Synced Sep 5, 2026, 11:26 AM EDT
Completed Phase 1 Interventional

Taurolidine in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT00021034
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
chemotherapy, taurolidine
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2013 · Synced Sep 5, 2026, 11:26 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

NCT06824467
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
Sacituzumab tirumotecan, Bevacizumab, H1 receptor antagonist, H2 receptor antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Steroid mouthwash (dexamethasone or equivalent)
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
36
States / cities
Birmingham, Alabama • Anchorage, Alaska • San Francisco, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 5, 2026, 11:26 AM EDT
Completed Phase 2 Interventional

Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer

NCT00074867
View directory record Official record
Conditions
Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms
Interventions
CP-547,632
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
7
States / cities
Los Angeles, California • Santa Monica, California • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2006 · Synced Sep 5, 2026, 11:26 AM EDT
Completed Phase 2 Interventional Results available

VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT01666444
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
pegylated liposomal doxorubicin (PLD), VTX-2337, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older · Female only
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
136
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Burbank, California + 104 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Sep 5, 2026, 11:26 AM EDT
Not listed Phase 1Phase 2 Interventional

Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer

NCT02785250
View directory record Official record
Conditions
Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Peritoneal Cancer
Interventions
DPX-Survivac, Cyclophosphamide, Epacadostat (INCB024360)
Other · Drug
Lead sponsor
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Industry
Eligibility
18 Years and older · Female only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
6
States / cities
Palo Alto, California • Augusta, Georgia • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2021 · Synced Sep 5, 2026, 11:26 AM EDT
Terminated Phase 1 Interventional

Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer

NCT01312376
View directory record Official record
Conditions
Ovarian Carcinoma, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
OC-DC vaccine, Bevacizumab, cyclophosphamide 300 mg/m2/d for 3 days, fludarabine 30 mg/m2/d for 3 days, ex vivo CD3/CD28-costimulated vaccine-primed peripheral blood autologous T cells
Biological · Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 23, 2020 · Synced Sep 5, 2026, 11:26 AM EDT
Completed Phase 2 Interventional

TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT00022347
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
canfosfamide hydrochloride
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2013 · Synced Sep 5, 2026, 11:26 AM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer

NCT02278783
View directory record Official record
Conditions
Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Interventions
regorafenib
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Sep 5, 2026, 11:26 AM EDT
Terminated Phase 2 Interventional Results available

Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT02569957
View directory record Official record
Conditions
Malignant Ovarian Endometrioid Tumor, Malignant Ovarian Serous Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Topotecan Hydrochloride, Acetylcysteine
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Sep 5, 2026, 11:26 AM EDT
Active, not recruiting Phase 1 Interventional

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

NCT05691504
View directory record Official record
Conditions
Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Fallopian Tube Carcinoma, Metastatic Platinum-Resistant Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Cobimetinib, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pelcitoclax
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Atlanta, Georgia • Baltimore, Maryland • Bethesda, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 5, 2026, 11:26 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT01962948
View directory record Official record
Conditions
Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
Interventions
paclitaxel, ganetespib, laboratory biomarker analysis
Drug · Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Sep 5, 2026, 11:26 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT01312389
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
OC-L/Montanide ISA 51 VG, Ampligen, Prevnar
Biological
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 14, 2021 · Synced Sep 5, 2026, 11:26 AM EDT
Completed Phase 2 Interventional

Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

NCT00006942
View directory record Official record
Conditions
Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
Interventions
bryostatin 1, cisplatin, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2013 · Synced Sep 5, 2026, 11:26 AM EDT
Completed Phase 2 Interventional Results available

Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT01540565
View directory record Official record
Conditions
BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ovarian Epithelial Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Laboratory Biomarker Analysis, Veliparib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
153
States / cities
Phoenix, Arizona • Concord, California • La Jolla, California + 114 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Sep 5, 2026, 11:26 AM EDT
Not listed Phase 3 Interventional

Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)

NCT02584478
View directory record Official record
Conditions
Endometrial Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Cervical Carcinoma
Interventions
AL3818, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD), Topotecan, Carboplatin
Drug
Lead sponsor
Advenchen Laboratories, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
8
States / cities
Long Beach, California • Miami, Florida • Lexington, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Sep 5, 2026, 11:26 AM EDT